title: Prognostic significance of copy-number alterations in multiple myeloma.
abstract: OBJECTIVE
  Chromosomal aberrations are a hallmark of multiple myeloma but their global prognostic impact is largely unknown.
  
  
  METHODS
  We performed a genome-wide analysis of malignant plasma cells from 192 newly diagnosed patients with myeloma using high-density, single-nucleotide polymorphism (SNP) arrays to identify genetic lesions associated with prognosis.
  
  
  RESULTS
  Our analyses revealed deletions and amplifications in 98% of patients. Amplifications in 1q and deletions in 1p, 12p, 14q, 16q, and 22q were the most frequent lesions associated with adverse prognosis, whereas recurrent amplifications of chromosomes 5, 9, 11, 15, and 19 conferred a favorable prognosis. Multivariate analysis retained three independent lesions: amp(1q23.3), amp(5q31.3), and del(12p13.31). When adjusted to the established prognostic variables (ie, t(4;14), del(17p), and serum beta(2)-microglobulin [Sbeta(2)M]), del(12p13.31) remained the most powerful independent adverse marker (P < .0001; hazard ratio [HR], 3.17) followed by Sbeta(2)M (P < .0001; HR, 2.78) and the favorable marker amp(5q31.3) (P = .0005; HR, 0.37). Patients with amp(5q31.3) alone and low Sbeta(2)M had an excellent prognosis (5-year overall survival, 87%); conversely, patients with del(12p13.31) alone or amp(5q31.3) and del(12p13.31) and high Sbeta(2)M had a very poor outcome (5-year overall survival, 20%). This prognostic model was validated in an independent validation cohort of 273 patients with myeloma.
  
  
  CONCLUSIONS
  These findings demonstrate the power and accessibility of molecular karyotyping to predict outcome in myeloma. In addition, integration of expression of genes residing in the lesions of interest revealed putative features of the disease driving short survival.
authors.affiliation: L'Institut National de la Santé et de la Recherche Médicale U892, Université de Nantes, Institut de Biologie, 9 Quai Moncousu, Nantes, 44093, France.
authors.forename: Hervé
authors.initials: H
authors.lastname: Avet-Loiseau
authors.forename: Cheng
authors.initials: C
authors.lastname: Li
authors.forename: Florence
authors.initials: F
authors.lastname: Magrangeas
authors.forename: Wilfried
authors.initials: W
authors.lastname: Gouraud
authors.forename: Catherine
authors.initials: C
authors.lastname: Charbonnel
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Harousseau
authors.forename: Michel
authors.initials: M
authors.lastname: Attal
authors.forename: Gerald
authors.initials: G
authors.lastname: Marit
authors.forename: Claire
authors.initials: C
authors.lastname: Mathiot
authors.forename: Thierry
authors.initials: T
authors.lastname: Facon
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Anderson
authors.forename: Loïc
authors.initials: L
authors.lastname: Campion
authors.forename: Nikhil C
authors.initials: NC
authors.lastname: Munshi
authors.forename: Stéphane
authors.initials: S
authors.lastname: Minvielle
mesh_terms: D002869:Chromosome Aberrations; D018628:Gene Dosage; D006801:Humans; D009101:Multiple Myeloma / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011237:Predictive Value of Tests; D011379:Prognosis
references.citation: Blood. 2003 Oct 1;102(7):2562-7
references.pmid: 12805059
references.citation: Mol Cell. 2002 Nov;10(5):1235-46
references.pmid: 12453429
references.citation: Blood. 1998 Aug 1;92(3):802-9
references.pmid: 9680348
references.citation: Blood. 2002 Mar 1;99(5):1745-57
references.pmid: 11861292
references.citation: Blood. 2006 Sep 15;108(6):2020-8
references.pmid: 16728703
references.citation: Cytokine Growth Factor Rev. 2008 Jun-Aug;19(3-4):199-207
references.pmid: 18499506
references.citation: Blood. 2001 Oct 1;98(7):2229-38
references.pmid: 11568011
references.citation: Blood. 2007 Mar 15;109(6):2276-84
references.pmid: 17105813
references.citation: Blood. 2003 Jun 1;101(11):4569-75
references.pmid: 12576322
references.citation: Blood. 1998 Apr 15;91(8):3007-10
references.pmid: 9531613
references.citation: Br J Haematol. 2003 Jul;122(2):193-201
references.pmid: 12846886
references.citation: Br J Haematol. 2006 Jan;132(2):168-70
references.pmid: 16398651
references.citation: Blood. 2002 Sep 1;100(5):1579-83
references.pmid: 12176874
references.citation: Am J Clin Pathol. 2006 Oct;126(4):545-51
references.pmid: 16938662
references.citation: Blood. 2006 Sep 1;108(5):1733-43
references.pmid: 16705090
references.citation: PLoS Comput Biol. 2006 May;2(5):e41
references.pmid: 16699594
references.citation: Blood. 2007 Nov 1;110(9):3291-300
references.pmid: 17609426
references.citation: Mol Cell Biol. 2008 Jul;28(14):4629-41
references.pmid: 18458058
references.citation: Blood. 2002 Mar 15;99(6):2185-91
references.pmid: 11877296
references.citation: Blood. 2000 Mar 15;95(6):1925-30
references.pmid: 10706856
references.citation: Br J Haematol. 2003 Apr;121(1):36-43
references.pmid: 12670329
references.citation: Nat Immunol. 2009 Jan;10(1):109-15
references.pmid: 19060901
references.citation: Cancer Res. 2007 Apr 1;67(7):2982-9
references.pmid: 17409404
references.citation: Blood. 2005 Jan 1;105(1):358-60
references.pmid: 15339849
references.citation: Blood. 2007 Apr 15;109(8):3489-95
references.pmid: 17209057
references.citation: Bioinformatics. 2004 May 22;20(8):1233-40
references.pmid: 14871870
references.citation: Br J Haematol. 2003 Jan;120(2):223-34
references.pmid: 12542479
references.citation: Br J Haematol. 2007 Oct;139(1):51-4
references.pmid: 17854306
references.citation: Mol Cell Biol. 1995 Oct;15(10):5376-88
references.pmid: 7565688
references.citation: Mol Cell Biol. 2005 Aug;25(16):6956-63
references.pmid: 16055709
references.citation: Cancer Res. 2002 Feb 1;62(3):715-20
references.pmid: 11830525
references.citation: Blood. 2001 Mar 15;97(6):1566-71
references.pmid: 11238092
references.citation: Biostatistics. 2004 Oct;5(4):557-72
references.pmid: 15475419
references.citation: Cancer Cell. 2007 Apr;11(4):349-60
references.pmid: 17418411
references.citation: Blood. 2003 Feb 15;101(4):1520-9
references.pmid: 12393535
references.citation: Leukemia. 2006 Nov;20(11):2034-40
references.pmid: 17024118
references.citation: Blood. 2004 Nov 1;104(9):2661-6
references.pmid: 15238415
references.citation: Mol Cell Biol. 2008 Jan;28(2):772-83
references.pmid: 18039850
references.citation: Blood. 2006 Sep 1;108(5):1724-32
references.pmid: 16705089
references.citation: Cancer Cell. 2007 Aug;12(2):115-30
references.pmid: 17692804
references.citation: J Clin Oncol. 2008 Oct 10;26(29):4798-805
references.pmid: 18591550
references.citation: Leukemia. 2007 Sep;21(9):2020-4
references.pmid: 17625611